Context Therapeutics, Inc. (CNTX)
2.435
-0.04
(-1.81%)
USD |
NASDAQ |
Feb 25, 12:10
Context Therapeutics Research and Development Expense (Quarterly) : 8.722M for Sept. 30, 2025
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 87.83M |
| Alnylam Pharmaceuticals, Inc. | 372.22M |
| Savara, Inc. | 20.59M |
| BioMarin Pharmaceutical, Inc. | 192.41M |
| Imunon, Inc. | 1.899M |